TD Cowen lowered the firm’s price target on Old Dominion (ODFL) to $183 from $188 and keeps a Hold rating on the shares. The firm noted they ...

TD Cowen analyst Andrew Kligerman maintained a Hold rating on Markel (MKL – Research Report) today and set a price target of $1,836.00. The ...

Anheuser-Busch Inbev SA (BUD) stock saw a modest uptick, ending the day at $49.11 which represents a slight increase of $0.41 or 0.84% from the prior close of $48.7. The stock opened at $49 and ...

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...

Mueller Water Products Inc (MWA) stock saw a modest uptick, ending the day at $26.93 which represents a slight increase of $3.85 or 16.68% from the prior close of $23.08. The stock opened at $23.72 ...

Wednesday, analysts at TD Cowen increased their price target on Fiserv (NYSE:FI) shares from $235.00 to $277.00, while retaining a Buy rating on the stock. The stock, currently trading at $229.53, has ...

OSI Systems, Inc. (NASDAQ: OSIS), today announced that it will present at the TD Cowen 46th Annual Aerospace & Defense Conference on Wednesday, February 12, 2025, at 10:45 AM ET.

The transportation sector will be impacted by Trump's new tariff regime. Parcel consolidators and freight forwarders - like ...

Johnson & Johnson (NYSE: JNJ) will present at the 45th Annual TD Cowen Healthcare Conference on Tuesday, March 4th, 2025. Management will participate in a fireside chat at 11:10 a.m. Eastern Time.

TD Cowen expressed concerns about valuation. “If Celsius can’t demonstrate a path back to growth, it could end up being valued at a multiple more similar to other ex-growth CPG companies,” the note ...

Noting that Ambry is a profitable testing laboratory that generates more than $300 million of revenue annually, the investment bank thinks that the deal will enable TEM to start generating positive ...

TD Cowen initiated coverage of KalVista (KALV) with a Buy rating and $30 price target The firm cites sebetralstat’s opportunity as the first oral acute therapy for hereditary angioedema attacks ...